Specifications tableSubject area*Genetics*More specific subject area*Copy number variant analysis*Type of data*Tables*How data was acquired*Copy number variants (CNVs) were detected from the DNA microarray-based genotypes using three independent computational algorithms*Data format*Filtered and analyzed*Experimental factors*The blood samples were collected from 243 Caucasian individuals with Inflammatory Bowel Disease (IBD) enrolled to The Manitoba IBD Cohort Study*Experimental features*The blood samples were genotyped using Illumina Omni2.5M-8 microarray. CNVs were detected using three independent computational algorithms: PennCNV, iPattern, and QuantiSNP*Data source location*Manitoba, Canada*Data accessibility*The list of filtered stringent CNVs was deposited to dbVar database at NCBI as the following:*<https://www.ncbi.nlm.nih.gov/dbvar/studies/nstd157/>Related research article*S. Frenkel, C.N. Bernstein, M. Sargent, W. Jiang, Q. Kuang, W. Xu, P. Hu, Copy number variation-based gene set analysis reveals cytokine signalling pathways associated with psychiatric comorbidity in patients with inflammatory bowel disease, Genomics. (2019).*[https://doi.org/10.1016/j.ygeno.2019.05.001](10.1016/j.ygeno.2019.05.001){#intref0015}*.***Value of the data**•The IBD CNV data set provides a valuable resource for identifying potential causal genes for IBDs and its drug targets.•It can be used as a baseline to compare and analyze the CNVs identified in other populations.•These data will be useful to researchers to investigate the contribution of CNVs to IBD and its subtypes

1. Data {#sec1}
=======

The presented report is a description of the CNVs identified in 243 IBD patients with Caucasian ethnicity enrolled in the Manitoba IBD Cohort Study [@bib1]. We genotyped 269 individuals with IBD using the Illumina Omni2.5M − 8 microarray. After sample quality control and population stratification analysis, we initially selected 246 IBD patients of Caucasian ethnicity. Three different CNV detection algorithms were applied to analyze the data: PennCNV [@bib2], iPattern [@bib3], and QuantiSNP [@bib4]. The detected CNVs were filtered under stringent quality control criteria for their size, probe content, and algorithm-specific quality score. The quality control workflow is presented in [Fig. 1](#fig1){ref-type="fig"}. The quality control criteria and corresponding number of disqualified samples are presented in [Table 1](#tbl1){ref-type="table"}. To obtain high-confidence calls, we removed the CNVs detected by only one of the three algorithms while the CNVs detected by two or three algorithms were merged by retaining the outer boundary [@bib5]. Numbers of CNVs detected by different algorithms are presented in [Fig. 2](#fig2){ref-type="fig"}. The examples of merging of the results obtained by three algorithms are presented on [Fig. 3](#fig3){ref-type="fig"}. Three IBD samples with extremely large number of detected CNVs were removed, which left 243 IBD samples for the further analysis. Of the remaining data, CNVs with significant overlap with the repeat rich regions, such as centromeres and telomeres, segmental duplications, and immunoglobulin regions, were excluded [@bib2], [@bib6]. [Table 2](#tbl2){ref-type="table"} contains numbers of CNVs detected by each algorithm, corresponding numbers of disqualified CNVs, CNVs qualified for merging, and removed due to overlapping with the repeat-rich regions.Fig. 1**Quality control and CNV detecting workflow.** Stringent CNV calling was conducted using variants detected by two or three calling algorithms, which were of sizes greater than 5 kb and spanned at least five array probes. SD: Standard deviation; LRR: Log R ratio; BAF: B allele frequency.Fig. 1Table 1QC criteria and their cutoffs for sample qualification and the corresponding number of disqualified samples.Table 1QC criterionQC cutoff for qualificationNumber of disqualified samplesCall rate\>95%3SD for BAFBetween −0.009 and 0.074SD for LRRBetween 0.042 and 0.1312Population outliersEuropean ancestry18Number of CNVs\<1453Fig. 2N**umber of CNVs detected by different algorithms for each size group.** Labels inside the bars indicate the exact number of CNVs detected for each category after sample and CNV quality control but before CNV merging. In the legends, iPN = iPattern; PCNV = PennCNV; and QSNP = QuantiSNP.Fig. 2Fig. 3**Examples of CNV deletion and duplication detected by all three algorithms.** CNV length and number of probes for each algorithm were provided. Start and end probe positions for each algorithm were presented on the corresponding bars. Outer start and end positions were used as start and end positions of the stringent CNV. **A**: An example of deletion found in chr21q22.3; **B**: An example of duplication found in chr13q14.11; **C**: the start and end positions of the CNV detected by each of the algorithms and corresponding number of probes. LRR: Log R ratio; BAF: B allele frequency.Fig. 3Table 2**Overview of the number of CNVs after each step of quality control.** Numbers of CNVs (deletions and duplications separately, and together) detected by each of the three algorithms, number of disqualified and qualified CNVs, number of CNVs detected by each combination of algorithms, and number of CNVs removed due to overlapping with the regions of chromosomal instability.Table 2DuplicationsDeletionsAll CNVs**Initially detected**PennCNV3776676310539iPattern35901019913789QuantiSNP111941841329607**Disqualified CNVs in QC**PennCNV129930664365iPattern82457756599QuantiSNP76151374721362**Qualified CNVs for merging**PennCNV247736976174iPattern276644247190QuantiSNP357946668245**Detected CNVs by two or three algorithms**PennCNV, iPattern, QuantiSNP131626823998PennCNV, QuantiSNP507300807iPattern, QuantiSNP330603933PennCNV, iPattern206888All stringent217336535826**Removed CNVs due to overlapping with regions of chromosomal instability**\>70% overlap with segmental duplication4406011041\>70% overlap with centromere, telomere or immunoglobulin region225228453Number of removed CNVs6437811424Final number of CNVs153028724402

After the quality control and filtering, 4,402 stringent CNVs remained for the analysis; of those, 2,872 were deletions and 1,530 duplications. The chromosomal distribution of the stringent CNVs is presented on [Table 3](#tbl3){ref-type="table"}; the same data is visually presented on [Fig. 4](#fig4){ref-type="fig"}.Table 3**Chromosomal distribution of the stringent CNVs.** Number of deletions and duplications in three size categories, summary numbers of deletions and duplications and the total number of CNVs were presented for each chromosome excluding sex chromosomes. del: deletion and dupl: duplication.Table 3Chromosome\<20 kbp, del/dupl20--200 kbp, del/dupl\>200 kbp, del/duplall sizes, del/duplall CNV179/3638/524/5121/932142126/8850/2920/4196/1213173141/4779/833/4223/1343574110/5453/401/5164/992635100/3656/393/2159/77236684/1898/422/8184/682527138/4447/2817/6202/782808137/3445/232/4184/612459111/4430/282/2143/742171072/2429/283/12104/6416811125/6215/132/4142/7922112149/1220/610/1169/742431354/1237/100/291/241151453/10105/122/23160/4520515122/210/120/3132/171491663/5041/459/3113/982111753/2016/842/471/1081791880/1712/40/092/211131918/2859/543/280/841642057/1936/81/194/28122216/1619/291/026/45712211/48/263/822/3860All autosomes1889/677903/75080/1032872/15304402Fig. 4**Chromosome view of the detected CNVs.** The CNVs were presented as tiles on the corresponding genomic positions. The colour of the tile indicated the CNV type: deletions are red, duplications are blue. The height of tile stack in each genomic region corresponds to the number of CNVs; if a genomic region contains more than 30 CNVs, only 30 tiles were presented. The figure was built using the Circos [@bib12] tool.Fig. 4

2. Experimental design, materials and methods {#sec2}
=============================================

2.1. Study population {#sec2.1}
---------------------

Individuals were enrolled in The Manitoba IBD Cohort Study -- a population-based longitudinal study of patients with IBD [@bib7], [@bib8]. At enrolment in the Cohort Study, participants were at least 18 years of age with a median disease duration of 4.3 years and maximal disease duration of 7 years. Participants were identified and recruited from a population-based registry, the University of Manitoba IBD Research Registry. The diagnosis of IBD was determined based on surgical, endoscopic, and histologic data. At the time of the cohort study recruitment, there were 3192 participants in the research registry. The Manitoba IBD Cohort Study was approved by the University of Manitoba Health Research Ethics Board, and participants provided written informed consent. Blood samples for genotyping were obtained from a total of 269 IBD patients.

2.2. Genotyping {#sec2.2}
---------------

Blood samples acquired from the 269 IBD patients in the cohort were genotyped using Illumina Infinium Omni2.5-8 microarray at The Centre for Applied Genomics (TCAG) in Toronto. Rigorous quality control (QC) procedures were performed on the resulting data. The Illumina Infinium Omni2.5-8 microarray contains a total of 2,372,784 markers for SNP and CNV analyses. Samples were processed using the manufacturer\'s recommended protocol; BeadChips were scanned on the Illumina BeadArray Reader using default settings. Analysis and intra-chip normalization were performed using Illumina\'s GenomeStudio software v.2011.1. Probes reclustering was conducted in the GenomeStudio using the project-specific samples to produce custom cluster file, which was applied to generate LogR ratios (LRR) and B Allele Frequencies (BAF) for the CNV detection.

2.3. Intensity quality control for CNV detection {#sec2.3}
------------------------------------------------

Quality control (QC) for SNPs was performed at the individual SNP level ([Table 1](#tbl1){ref-type="table"}). Samples were excluded from the analysis if they had: i) array call rate \<95%; ii) standard deviation (SD) for LRR and BAF values outside mean ± 3SD for SD of an analysis batch. Closely related samples (by identity-by-descent distance for each pair of individuals), duplicates, samples with gender mismatches (by X chromosome homozygosity rate) or Mendelian error rate \>1% were excluded from the analysis batch.

2.4. Population stratification analysis {#sec2.4}
---------------------------------------

The reference population for population stratification analysis using multidimensional scaling (MDS) was obtained from Phase 3 data of 1000 Genomes Project [@bib9]. Population stratification was conducted using PLINK [@bib10] version 1.07. All ethnicity outliers were removed so that only samples of European ancestry were used in this study.

2.5. CNV calling algorithms {#sec2.5}
---------------------------

For comprehensive detection of CNVs in the IBD patients, we ran three CNV calling algorithms, namely, PennCNV [@bib2], iPattern [@bib3], and QuantiSNP [@bib4]. The required data for CNV analysis, i.e. within-sample normalized fluorescence (i.e. X and Y normalized values), between-sample normalized fluorescence (i.e. Log R ratios (LRR) and B allele frequency (BAF) values) and genotypes for each sample, were exported directly from Illumina\'s Genomestudio software. Only autosomal probes were used in the CNV analysis. In summary, 10539, 13789 and 29607 CNVs were detected by PennCNV, iPattern and QuantiSNP, correspondingly ([Table 2](#tbl2){ref-type="table"}). We excluded the CNVs if they failed the following quality control criteria: \<5 probes, \<5000 bp in length and low algorithm-specific confidence score (PennCNV confidential score \< 15, QuantiSNP Log Bayes Factor \< 10 or iPattern score \< 1). After this filtering, 6174, 7190 and 8245 CNVs were identified as high quality CNVs calls for PennCNV, iPattern and QuantiSNP, respectively. Each algorithm performed differently in calling CNVs of different sizes, with PennCNV being the most conservative in detection of CNVs, while QuantiSNP was least conservative except for large (\>200 kbp) CNVs ([Fig. 2](#fig2){ref-type="fig"}).

2.6. CNV merging {#sec2.6}
----------------

To obtain stringent CNV calls, we merged high quality CNVs detected by at least two of the three algorithms using outer probe boundaries ([Fig. 3](#fig3){ref-type="fig"}). All CNVs detected by only one algorithm were excluded from the further analysis. As an additional step of sample QC, we excluded three samples with excessive number of stringent CNVs. We removed the samples with more than 145 CNVs (as the mean number of CNVs plus 3 SD). After CNV merging, 5826 CNVs were considered as stringent. 2173 and 3653 of the CNVs are duplications and deletions, respectively (see [Table 2](#tbl2){ref-type="table"}).

2.7. CNV filtering {#sec2.7}
------------------

We further excluded CNVs that: 1) overlapped the centromere (100 kbp regions before and after centromeres) or the telomere (100 kb from the ends of the chromosome); 2) had \> 70% of its length overlapping a segmental duplication using the entire segmental duplication dataset downloaded from the University of California, Santa Cruz (UCSC) Genome Browser website [@bib11]; 3) had \>70% overlap with immunoglobulin region (susceptible to somatic changes) [@bib2], [@bib6].

The final CNV data set includes a total of 4402 CNVs, 2872 and 1530 of which were deletions and duplications, respectively ([Fig. 4](#fig4){ref-type="fig"}). The final list of stringent CNVs is available in the dbVar database at NCBI: ***nstd157***. Of all CNVs, 58.3% were smaller than 20 kbp, while 4.2% covered more than 200 kbp. Chromosomal distribution of the stringent deletions and duplications in three size categories (less than 20 kbp, 20--200 kbp and more than 200 kbp) were presented in the [Table 3](#tbl3){ref-type="table"}.
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